K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 acquired 8.88% stake in Biocore Co., Ltd. from Kwang-Hyun Lee and Seung-Hyun Lee for KRW 4 billion.
October 27, 2015 at 09:30 am IST
Share
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 acquired 8.88% stake in Biocore Co., Ltd. from Kwang-Hyun Lee and Seung-Hyun Lee for KRW 4 billion on October 20, 2015. K2 Asset Securitization Specialty Investment Fund acquired 0.18 million shares from Kwang-Hyun Lee, Korea Omega Venture Investment No.1 Fund acquired 0.09 million shares from Seung-Hyun Lee, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 acquired 0.04 million shares each from Seung-Hyun Lee. The shares were acquired at a price of KRW 11000 each. Kwang-Hyun Lee and Seung-Hyun Lee now hold 0.08 million shares and 0.07 million shares respectively.
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 completed the acquisition of 8.88% stake in Biocore Co., Ltd. from Kwang-Hyun Lee and Seung-Hyun Lee on October 20, 2015.
Invites Biocore Co Ltd, formerly BioCore Co Ltd, is a Korea-based company mainly engaged in the provision of medical examination services. The Company operates its business through two segments. The New Drug Development Business segment is involved in the provision of bioequivalence testing, drug in vivo kinetics research, drug analysis in biological samples, toxicity kinetics testing, microanalysis in pharmaceuticals, comparative dissolution testing, and clinical trial consulting. The Biotechnology Business segment is engaged in the provision of customized genome analysis services and the manufacture and sale of diagnostic kits. The Companyâs products are sold under the brand of Bio-Core.
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 acquired 8.88% stake in Biocore Co., Ltd. from Kwang-Hyun Lee and Seung-Hyun Lee for KRW 4 billion.
INVITES BIOCORE CO., LTD. 
